MedTrace Logo

Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies

NCT01178346 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2012-05-09

No results posted yet for this study

Summary

The purpose of this study is to look at pharmacoeconomic data for subjects that have received either NicVAX or placebo in the Nabi-4514 or Nabi-4515 studies.

Conditions

  • Smoking Cessation

Interventions

BIOLOGICAL

NicVAX vaccine

NicVAX vaccine given 6 times over 6 months

BIOLOGICAL

Placebo

Placebo vaccine given 6 times over 6 months

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Nabi Biopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Nabi Biopharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01178346 on ClinicalTrials.gov